Table 2.
Comparison of symptoms after the first dose in patients with IBD (study) group vs. healthy participants (control) group.
| Characteristic | Study group, N = 102 a | Control group, N = 102 a | P b |
|---|---|---|---|
| Age_in years | 33 (26, 41) | 34 (28, 43) | |
| Gender | |||
| Female | 48 (47%) | 52 (51%) | |
| Male | 54 (53%) | 50 (49%) | |
| Injection site | |||
| Pain | 38 (37%) | 58 (57%) | 0.005 |
| Redness | 3 (2.9%) | 17 (17%) | <0.001 |
| Swelling | 4 (3.9%) | 18 (18%) | 0.002 |
| Systemic AEs | |||
| Tiredness | 19 (19%) | 35 (34%) | 0.011 |
| Headache | 15 (15%) | 16 (16%) | 0.8 |
| Muscle pain | 11 (11%) | 24 (24%) | 0.016 |
| Chills | 4 (3.9%) | 14 (14%) | 0.014 |
| Fever | 13 (13%) | 14 (14%) | 0.8 |
| Nausea | 1 (1.0%) | 9 (8.8%) | 0.009 |
| Joint pain | 8 (7.8%) | 11 (11%) | 0.5 |
a
Median (IQR) or frequency (%).
b
Wilcoxon rank sum test; Pearson's Chi-squared test.